BioBridgeX
Log inCompare quotes
Preclinical / Nonclinical

In Vivo Pharmacology & Efficacy CROs

Free for buyersNeutral vendor of record
Quick answer

In vivo pharmacology and efficacy studies test a drug candidate in living animal models to prove it works at a tolerable dose before you commit to costly IND-enabling toxicology. You need it in preclinical development, after in vitro potency looks good. On BioBridgeX, buyers source and compare qualified CROs under one contract, free for buyers.

In Vivo Pharmacology & Efficacy CROs on BioBridgeX

We are qualifying and publishing In Vivo Pharmacology & Efficacy CROs now. Tell us what you need and we will match you with vetted vendors, or list your organization to be among the first.

What is In Vivo Pharmacology & Efficacy and when do you need it?

In vivo pharmacology and efficacy is where you take a candidate that looked good in a dish and ask whether it actually does anything in a living animal. In vitro work tells you a compound binds its target and moves a cellular readout. It cannot tell you whether enough drug reaches the right tissue, stays there long enough, and produces a real disease-modifying effect at a dose the animal tolerates. That gap is exactly what an in vivo efficacy study closes, and it is one of the hardest go/no-go gates in the whole preclinical stage.

You commission this work once you have a lead (or a short panel of leads) with credible in vitro potency and at least a rough read on exposure, and before you spend real money on GLP toxicology. The point is to generate proof of concept: a clear, dose-responsive effect in a model that maps to your indication. For an oncology program that usually means tumor growth inhibition in a xenograft, syngeneic, PDX, or humanized model. For other therapeutic areas it means a validated disease model with a functional or biomarker endpoint that a reviewer and your own board will take seriously.

Treat the in vivo readout as the candidate's audition. A weak or noisy efficacy result here is the cheapest place in the program to kill a molecule or pick a different lead, far cheaper than discovering the problem after you have funded a two-species tox package. The studies in this category are typically non-GLP and built to inform decisions, not to file, though the way you design them (dose selection, control groups, statistical power, PK sampling alongside the efficacy readout) directly shapes how defensible your IND story will be later.

What does an In Vivo Pharmacology & Efficacy CRO actually do?

A good in vivo CRO is part contract laboratory and part study-design partner. They run the animal work, but the value sits in helping you pick the right model, the right doses, and the right endpoints so the result answers your actual question. The day-to-day work spans model setup, dosing and in-life monitoring, the efficacy readout, and the tissue and PK analysis that lets you connect dose to exposure to effect.

Most programs lean on a CRO because standing up and validating a disease model in-house is slow and expensive, and a specialist already has the model running with historical control data. That history matters: a vendor who has dosed your specific xenograft line or autoimmune model dozens of times knows its baseline variability, which protects you from a study that fails on noise rather than on biology.

  • Study design and model selection: choosing and justifying the model (xenograft, syngeneic, PDX, genetically engineered, humanized for immuno-oncology, or a TA-specific disease model), group sizes, randomization, and a power calculation so the study can actually detect the effect you expect.
  • Dosing and route optimization: setting dose levels, schedule, and route (IV, oral, IP, SC) informed by your DMPK data, plus formulation and vehicle work so the compound is dosed cleanly.
  • In-life conduct: animal acclimation, dosing, body-weight and clinical monitoring, and welfare oversight under AAALAC accreditation and an approved IACUC protocol.
  • Efficacy readouts: the primary endpoint that defines success, such as tumor growth inhibition and tumor volume curves in oncology, or functional, behavioral, and biomarker endpoints in other indications.
  • PK/PD bridging: satellite PK sampling and pharmacodynamic biomarkers run alongside the efficacy arm so you can tie exposure to effect rather than reporting dose alone.
  • Terminal analysis and reporting: tissue collection, histology, flow cytometry or IHC where relevant, and a clear written report with the raw data, statistics, and an honest account of any animals lost or doses that did not hold.

How to choose an In Vivo Pharmacology & Efficacy CRO?

Start with model and modality fit, not the headline quote. A site that runs flawless oncology xenografts may have no experience with a CNS behavioral model or an AAV gene therapy, where the live questions are biodistribution and durability of effect rather than tumor shrinkage. The single most useful question you can ask is whether the CRO already has your specific model validated and running, with historical control data, instead of building it for the first time on your budget and your timeline.

From there, the decision comes down to a short list of practical checks. Capacity and the current animal-room queue often matter more than science, because a great lab booked solid for months can be slower than a good lab with an open slot. Confirm animal welfare accreditation and a clean track record, because a study that stumbles on welfare or quality is a study you cannot use. And weigh data quality and honest reporting heavily: a cheap study you cannot defend, or cannot reconcile against your own expectations, is the most expensive outcome in this category.

  • Quality and GxP status: in vivo efficacy is usually non-GLP, but confirm documented SOPs, data-integrity practices, and AAALAC accreditation with an approved IACUC protocol, so the non-GLP data holds up internally and dose-range-finding can flow cleanly into the later GLP tox program.
  • Capacity and lead time: ask about the current animal-room queue, model availability, and realistic timelines for acclimation, in-life, tissue analysis, and the final report, not just the bench portion.
  • Modality and indication fit: match the vendor to your modality (small molecule, antibody, ADC, oligonucleotide, cell or gene therapy) and your therapeutic area, and confirm the disease model and endpoint actually map to your indication.
  • Region and regulatory track record: confirm the site can support an FDA, EMA, or other regional filing path, and that its study design and documentation will stand up when this proof of concept is cited in your IND.
  • Data quality and reporting: look for historical control data, transparent statistics with a real power calculation, and a willingness to report failed arms and lost animals plainly rather than smoothing them over.
  • IP and confidentiality: settle who owns the data and any derived findings before work starts, and put a CDA in place, especially if the target or model is something you do not want disclosed.

Frequently asked questions

What is the difference between in vitro and in vivo pharmacology?
In vitro pharmacology tests your compound in biochemical or cell-based assays: target binding, selectivity, dose-response (IC50/EC50), and off-target liabilities. In vivo pharmacology tests it in a living animal to show a real, dose-responsive effect in a disease-relevant model, such as tumor growth inhibition in a xenograft or a functional readout in a TA-specific model. In vitro tells you the mechanism works at the molecular level. In vivo tells you whether it translates into efficacy at an exposure the animal tolerates, which is the question that justifies funding the expensive IND-enabling work that follows.
Do in vivo efficacy studies need to be GLP compliant?
Usually not. In vivo pharmacology and efficacy work is typically non-GLP because its job is to inform your go/no-go decisions, not to satisfy a regulator. GLP (21 CFR Part 58, or OECD GLP outside the US) governs the pivotal safety studies in the IND-enabling stage. Non-GLP does not mean low quality, though: the data still has to be solid enough to bet a program on, run under documented SOPs and AAALAC-accredited animal welfare. The dose-range-finding you do here also feeds directly into the later GLP tox design, so good documentation now pays off twice.
Which animal model should I use for an in vivo efficacy study?
It depends on your indication and modality, and choosing the model is half the study design. In oncology, cell-line xenografts are fast and cheap but limited, syngeneic models let you study immune-active mechanisms in an intact immune system, PDX models better reflect patient tumor heterogeneity, and humanized models are used for immuno-oncology agents that target human immune cells. Outside oncology you match a validated disease model to the mechanism and endpoint that matter for your program. A strong CRO will help you justify the choice and should already have the model running with historical control data.
How long does an in vivo efficacy study take?
Plan in months rather than weeks for a full readout. The clock includes animal acclimation, model establishment (tumor implantation and growth to a target size, or disease induction), the dosing and observation window, and terminal tissue and PK analysis, plus report writing on the back end. An efficacy study with a long readout window, or one gated on a slow-growing model, takes longer than a simple short-term pharmacodynamic study. CRO capacity and the current animal-room queue often drive the start date more than the science does, so lock the slot early.
How much does an in vivo pharmacology and efficacy study cost?
Cost depends on the model, the number of arms and animals, dosing complexity, and the depth of terminal analysis, so any vendor quoting a flat number before seeing your study design is guessing. As a rough shape, simple short-term pharmacodynamic studies sit at the lower end, standard efficacy studies in established models sit in the middle, and specialized models (PDX, humanized, or bespoke genetically engineered lines) cost more. The way to control spend is sequencing: run a tight, well-powered proof-of-concept study first, retire weak leads, and only scale up once a candidate has earned it.
Can one CRO run both the efficacy study and the supporting PK?
Often yes, and it is usually worth pairing them. Running satellite PK sampling and pharmacodynamic biomarkers alongside the efficacy arm lets you tie exposure to effect instead of reporting dose alone, which makes the result far more defensible. Some in vivo pharmacology CROs run DMPK and bioanalytical in-house; others specialize in the animal work and partner for the assay. On BioBridgeX you can source the efficacy CRO and a DMPK or bioanalytical vendor together and contract once, with one purchase order and one invoice across all of them, so the methods are ready before samples come off the study.

Source In Vivo Pharmacology & Efficacy with one contract

Compare transparent quotes from qualified In Vivo Pharmacology & Efficacy CROs, then contract once. Free for buyers.

Compare quotes